PARSIPPANY, New Jersey & CAMBRIDGE, Massachusetts — March 3, 2026
March 3, 2026: Teva Pharmaceutical Industries and funds managed by Blackstone Life Sciences have announced a $400 million strategic growth capital agreement designed to accelerate the clinical development of duvakitug, a promising human monoclonal antibody targeting the TL1A pathway. The funding will be provided over four years and will support ongoing late-stage clinical trials of the therapy, which is currently being evaluated in Phase 3 studies for ulcerative colitis and Crohn’s disease. The agreement represents a major investment in the development of next-generation immunology therapies aimed at treating inflammatory bowel disease (IBD), a chronic autoimmune condition affecting millions of patients worldwide. The transaction also aligns with Teva’s “Pivot to Growth” strategy, which focuses on strengthening the company’s innovative medicine pipeline and accelerating the development of high-impact therapies.
Strategic Funding Accelerates Immunology Drug Development
The newly announced partnership provides $400 million in development funding to help advance duvakitug through late-stage clinical trials and regulatory pathways. Under the terms of the agreement, Blackstone Life Sciences will finance a portion of the development costs associated with the therapy’s clinical program.
In return, the investment firm will become eligible for future milestone payments tied to regulatory approvals and commercial performance, as well as low single-digit royalties on worldwide sales of the drug if it receives regulatory approval.
In return, the investment firm will become eligible for future milestone payments tied to regulatory approvals and commercial performance, as well as low single-digit royalties on worldwide sales of the drug if it receives regulatory approval.
Advertisement
The collaboration highlights the growing role of strategic life-science investment partnerships in accelerating the development of innovative medicines. By leveraging external capital, pharmaceutical companies are increasingly able to expand their research pipelines while maintaining financial stability.
For Teva, the partnership represents a significant step toward advancing its long-term transformation into a leading innovative biopharmaceutical company, complementing its global generics business with a stronger portfolio of specialty medicines.
Duvakitug Targets Inflammation Pathway in IBD
Duvakitug is a human monoclonal antibody designed to inhibit TL1A signaling, a biological pathway believed to play a central role in the inflammatory processes associated with inflammatory bowel disease (IBD). TL1A interacts with the DR3 receptor, triggering immune responses that contribute to intestinal inflammation and tissue fibrosis.
By selectively blocking the TL1A-DR3 signaling pathway, duvakitug is designed to reduce inflammation and potentially limit fibrotic damage within the gastrointestinal tract. This mechanism could offer new therapeutic benefits for patients suffering from chronic inflammatory diseases such as Ulcerative Colitis and Crohn’s Disease.
Both conditions are characterized by recurring cycles of inflammation in the digestive tract, leading to symptoms including persistent diarrhea, abdominal pain, fatigue, and weight loss. Long-term inflammation can cause structural damage to the intestinal wall, resulting in complications such as fibrosis, intestinal narrowing, and obstruction.
Recent clinical data from Phase 2b maintenance studies demonstrated clinically meaningful and durable efficacy signals for duvakitug in patients with ulcerative colitis and Crohn’s disease, supporting the ongoing Phase 3 development program.
Addressing a Growing Global Health Challenge
Inflammatory bowel disease represents a growing global health concern. Epidemiological studies estimate that approximately 4.9 million people worldwide are currently affected by IBD, and the prevalence continues to increase across many regions. Despite advances in biologic therapies, there is still no cure for the disease, and many patients experience incomplete responses to existing treatments.
Current treatment strategies aim to induce and maintain remission while preventing disease flares and long-term complications. However, a significant proportion of patients continue to suffer from persistent inflammation, highlighting the urgent need for new therapeutic options.
Researchers believe that targeting the TL1A inflammatory pathway could represent a major advancement in IBD treatment, as it addresses both inflammatory signaling and fibrotic processes associated with disease progression. If successful, duvakitug may emerge as a best-in-class therapy in the rapidly growing immunology drug market, offering new hope to patients with moderate to severe inflammatory bowel disease.
Partnership Strengthens Innovation Strategy
The investment agreement also reflects the continued collaboration between Teva and Sanofi, which are jointly developing and planning to co-commercialize duvakitug pending regulatory approval. Combining scientific expertise with strategic financial investment may accelerate the therapy’s path to market while expanding treatment options for patients with autoimmune diseases.
Industry experts note that innovative biologic therapies targeting immune pathways are becoming a central focus of modern drug development, particularly in areas with high unmet medical need. By supporting the continued development of duvakitug, the new partnership aims to bring a promising new immunology treatment closer to patients suffering from chronic gastrointestinal inflammation.
z
Source: teva pharmaceuticals press release
